CRIS: Expands Clinical Sites
Curis expands clinical sites in TakeAim CLL study and reaffirms patient dosing guidance
CRIS CRIS - Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split